Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
661-680 of 1,307 trials

Thyroid Eye Disease: Sirolimus vs. Corticosteroids

We are comparing a new treatment called Sirolimus with corticosteroids for people with active thyroid eye disease. The goal is to see if Sirolimus is more effective and has fewer side effects.

Thyroid Eye Disease≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOphthalmology

Long-Term Study of Galapagos CAR T-Cell Therapies

We are evaluating the long-term safety and effectiveness of Galapagos CAR T-cell therapies in patients. This study aims to understand how these treatments work over many years.

Relapsed/Refractory B-Cell Non-Hodgkin LymphomaRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Overactive Bladder in Children: BeDry Study

We are testing solifenacin, mirabegron, and their combination for treating daytime urinary incontinence in children aged 5 to 14. The study aims to see how well these treatments work and their effects on safety and quality of life.

Daytime Urinary Incontinence3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesPediatricsUrology

Acute Agitation: Comparing New Medications

We are studying how well sublingual dexmedetomidine and buccal midazolam work for calming patients in emergency settings compared to oral lorazepam. We also want to know about their safety and how satisfied patients feel with these treatments.

Acute Agitation>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPsychiatry

GSDIa: DTX401 Treatment Study

We are examining the long-term safety and pregnancy outcomes of DTX401 for individuals with GSDIa. This study will help us understand how effective this treatment is over time.

Glycogen Storage Disease Type IA>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Niemann-Pick Disease Type C: N-Acetyl-L-Leucine Study

We are investigating whether N-Acetyl-L-Leucine can improve symptoms and quality of life for individuals with Niemann-Pick disease type C. The study also looks at the safety of this treatment for both older and younger patients.

Niemann-Pick Disease Type C3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyNeurology

Chronic Graft-Versus-Host Disease: Axatilimab Treatment

We are studying whether axatilimab, combined with corticosteroids, helps improve symptoms in patients with moderate to severe chronic graft-versus-host disease. This trial compares its effects to a placebo.

Chronic Graft-Versus-Host DiseaseConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Chronic Lymphocytic Leukemia: Venetoclax and Pirtobrutinib Study

We are comparing different treatment plans for newly diagnosed chronic lymphocytic leukemia patients to see if a personalized approach improves outcomes. This includes assessing how long patients can stay in remission and the overall effectiveness of the treatments.

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Pamidronate for Pain in Sternocostoclavicular Hyperostosis

We are studying whether pamidronate can help reduce pain in patients with sternocostoclavicular hyperostosis. This trial will also look at improvements in daily activities and overall health.

Inflammation of the Sternal RegionSternocostoclavicular Hyperostosis1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Head and Neck Cancer: Petosemtamab Treatment Study

We are studying the effects of petosemtamab in patients with advanced head and neck cancer who have not responded to previous treatments. The goal is to see if it improves survival and tumor response compared to standard therapies.

Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Head and Neck Cancer: Petosemtamab with Pembrolizumab

We are studying a new treatment combination for patients with recurrent or metastatic head and neck cancer to see if it works better than standard treatment. This trial is for those with tumors that express PD-L1.

Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Uveal Melanoma: Tebentafusp Treatment Study

We are studying whether the drug tebentafusp can help prevent cancer recurrence in patients with high-risk uveal melanoma after surgery or radiation. This trial also looks at the safety of the treatment compared to observation.

Uveal Melanoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOphthalmology

Paroxysmal Nocturnal Hemoglobinuria: Pozelimab and Cemdisiran Therapy

We are studying the long-term safety and effectiveness of a combination therapy for adults with Paroxysmal Nocturnal Hemoglobinuria. This trial will help us understand its impact on symptoms like fatigue and hemoglobin levels.

Paroxysmal Nocturnal Hemoglobinuria>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Recurrent Herpes Labialis: Lipovir® Gel vs. Zovirax® Cream

We are studying whether Lipovir® Gel is as effective and tolerable as Zovirax® Cream for treating recurrent herpes labialis. Participants will also receive a placebo to help us understand the treatments better.

Cold Sores≤3 monthsConfirmation phase (III)Standard MedicinesDermatologyInfectious Diseases

Acne Vulgaris: N-Acetyl-GED-0507-34-Levo Gel

We are testing a new gel for people with acne vulgaris to see if it is safe and effective compared to a placebo. Participants will apply the gel once daily for the study.

Acne3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

Hypereosinophilic Syndrome: Depemokimab Study

We are investigating whether Depemokimab can help adults with Hypereosinophilic Syndrome manage their symptoms better than a placebo. This study aims to provide insights into its effectiveness and safety.

Hypereosinophilic Syndrome1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Pneumococcal Vaccine Response: Age and HIV Impact

We are studying how age and HIV infection affect the immune response to pneumococcal vaccination. This research aims to improve vaccine effectiveness for different populations.

HIV Infection6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Metformin for Prolonging Pregnancy in Preterm Preeclampsia

We are studying whether metformin can help extend pregnancy by at least 5 days in individuals with preterm preeclampsia. Additionally, we aim to see if it improves health outcomes for mothers and their babies.

Pre-eclampsiaHELLP SyndromeHypertensive Disorders of Pregnancy>2 yearsConfirmation phase (III)Investigational MedicinesGynecology and ObstetricsInternal Medicine

Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

Newly Diagnosed Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Cirrhosis Treatment: Pegozafermin Study

We are studying a new medication, pegozafermin, for individuals with compensated cirrhosis due to MASH. The goal is to see if it can improve liver health and reduce related health risks compared to a placebo.

Chronic Liver Disease and Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyHepatology